Vildagliptin | place in therapy review Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor LAF237 improves glycemic control in patients with type 2 diabetes. Diabetes. 2004;53(Suppl. 2):A83. Abstract 355-OR. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38:423–428. Pratley RE, Rosenstock J, Pi-Sunyer FX, Couturier A, Schweizer A, Dejager S. Efficacy and safety of vildagliptin in the elderly: pooled analysis of 5 monotherapy studies. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007b. Abstract 0887. Available at: http://www.easd. org/ (accessed October 11, 2007). Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692–698. Rolin B, Nygaard H, Wilken M, Kanstrup AB, Carr RD. The novel, xanthine-based, DPPIV inhibitor NN7201 and LAF237 improve glucose tolerance but do not prevent progression of diabetes in Zucker diabetic fatty rats. Presented at the American Diabetes Association Scientific Sessions, 2004. Abstract 1417-P. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed December 12, 2005). Rosenstock J, Baron MA, Camisasca RP, Cressier F, Cautier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007a;9:175–185. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care. 2007b;30:217–223. Rosenstock J, Rendell MS, Landin-Olsson M, Foley JE, Rochette E, Baron MA, Dejager S. Effects of vildagliptin in subjects with IGT. Presented at the American Diabetes Association Annual Meeting, 2007c. Abstract 0505-P. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed October 11, 2007). Rosenstock J, Pi-Sunyer FX, Banerji MA, Couturier A, Schweizer A, Dejager S. Consistent efficacy and safety of vildagliptin monotherapy across ethnicities. Presented at the American Diabetes Association Annual Meeting, 2007d. Abstract 2141-PO. Available at: http://scientificsessions.diabetes.org/Abstracts/ index.cfm (accessed October 11, 2007). Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care. 2001;24:447–453. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia. Presented at the American Diabetes Association Annual Meeting, 2007. Abstract 0503-P. Available at: http://scientificsessions.diabetes. org/Abstracts/index.cfm (accessed October 11, 2007). Schweizer A, Couturiert A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Med. 2007;24:955–961. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431. Serra DB, He Y-L, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction. Presented at the American Diabetes Association Scientific Sessions, 2005. Abstract 2192-PO. Available at: http://scientificsessions. diabetes.org/Abstracts/index.cfm (accessed December 12, 2005). Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346. Thuren T, Byiers S, Mohideen P. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007. Abstract 0881. Available at: http://www.easd.org/ (accessed October 11, 2007). Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161. Erratum in: Diabetes Care. 2004;27:856. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350. Turner RC, Cull CA, Frighi V, Homan R; The UKPDS Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). JAMA. 1999;281:2005–2012. UKPDS (UK Prospective Diabetes Study) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998a;352:854–865. UKPDS (UK Prospective Diabetes Study) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998b;352:837–853. Utzschneider KM, Tong J, Udayasankar J, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves insulin sensitivity and beta-cell function in subjects with impaired fasting glucose. Presented at the American Diabetes Association Annual Meeting, 2007. Abstract 0515-P. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed October 11, 2007). Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56:1475–1480. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003;46:2774–2789. WHO (World Health Organization). Screening for type 2 diabetes. Report of a World Health Organization and International Federation Meeting 2003. Available at http://www.who.int/diabetes/publications/en/screening_mnc03.pdf (accessed November 7, 2005). Zander M, Madsbad S, Madsen JL, Holst J. Effect of a 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830. Correspondence: Paul Chrisp, Core Medical Publishing, Mere House, Brook Street, Knutsford, Cheshire WA16 8GP, UK or at editor@coreevidence.com 30 © 2008 Core Medical Publishing Limited